Jaime Merchan, MD

home / authors / jaime-merchan-md

Jaime Merchan, MD, is a professor, co-leader of the Translational and Clinical Oncology Research Program, and director of the Phase 1 Clinical Trials Program at the Sylvester Comprehensive Cancer Center at the University of Miami.

Articles

Evaluating Belzutifan for Clear Cell Renal Cell Carcinoma Treatment

Jaime Merchan, MD

December 15th 2024

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

LITESPARK-013: Dose Comparison of Belzutifan in Advanced RCC

Jaime Merchan, MD

November 18th 2024

Jaime Merchan, MD, discusses the background and findings from the LITESPARK-013 trial of belzutifan for the treatment of patients with advanced clear cell renal cell carcinoma.

Merchan’s Takeaways From the CLEAR Study in Advanced RCC

Jaime Merchan, MD

October 7th 2024

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).

CLEAR Study Biomarker Analysis: Lenvatinib/Pembrolizumab vs Sunitinib Advanced Kidney Cancer

Jaime Merchan, MD

June 14th 2024

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.